An increase in glucosylceramide synthase induces BclxL-mediated cell survival in vinorelbine-resistant lung adenocarcinoma cells

Wei Hsin Chiu, Wu Chou Su, Chia Ling Li, Chia Ling Chen, Chiou Feng Lin

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Reversing drug resistance with concurrent treatment confers anticancer benefits. In this study, we investigated the potential mechanism of glucosylceramide synthase (GCS)-mediated vinca alkaloid vinorelbine (VNR) resistance in human lung adenocarcinoma cells. Compared with PC14PE6/AS2 (AS2) and CL1-0 cells, apoptotic analysis showed that both A549 and CL1-5 cells were VNR-resistant, while these cells highly expressed GCS at the protein level. VNR treatment significantly converts ceramide to glucosylceramide in VNR-resistant cells; however, pharmacologically inhibiting GCS with (±)-threo-1-Phenyl-2-decanoylamino-3-morpholino-1-propanol hydrochloride (PDMP) induced ceramide accumulation, accompanied by a decrease in glucosylceramide. Under concurrent treatment with VNR and PDMP, an increase in cell apoptosis could be identified; furthermore, genetically silencing GCS confirmed these effects. In VNR-resistant cells, Bcl-xL expression was aberrantly increased, while pharmacologically inhibiting Bcl-xL with ABT-737 sensitized cells to VNRinduced apoptosis. Conversely, enforced expression of Bcl-xL strengthened the survival response of the VNR-susceptible cells AS2 and CL1-0. Without changes in mRNA expression, Bcl-xL was overexpressed independent of β-catenin-mediated transcriptional regulation in VNR-resistant cells. Simultaneous GCS inhibition and VNR treatment caused a decrease in Bcl-xL expression. According to these findings, an increase in GCS caused Bcl-xL augmentation, facilitating VNR resistance in lung adenocarcinoma cells.

Original languageEnglish
Pages (from-to)20513-20524
Number of pages12
JournalOncotarget
Volume6
Issue number24
Publication statusPublished - 2015

Fingerprint

ceramide glucosyltransferase
Cell Survival
Glucosylceramides
Ceramides
vinorelbine
Adenocarcinoma of lung
Vinca Alkaloids
Apoptosis
Catenins

Keywords

  • Bcl-xL
  • Glucosylceramide synthase
  • Lung cancer
  • Multiple drug-resistances
  • Vinorelbine

ASJC Scopus subject areas

  • Oncology

Cite this

An increase in glucosylceramide synthase induces BclxL-mediated cell survival in vinorelbine-resistant lung adenocarcinoma cells. / Chiu, Wei Hsin; Su, Wu Chou; Li, Chia Ling; Chen, Chia Ling; Lin, Chiou Feng.

In: Oncotarget, Vol. 6, No. 24, 2015, p. 20513-20524.

Research output: Contribution to journalArticle

@article{21862286eeb245ea8ee514d56454618e,
title = "An increase in glucosylceramide synthase induces BclxL-mediated cell survival in vinorelbine-resistant lung adenocarcinoma cells",
abstract = "Reversing drug resistance with concurrent treatment confers anticancer benefits. In this study, we investigated the potential mechanism of glucosylceramide synthase (GCS)-mediated vinca alkaloid vinorelbine (VNR) resistance in human lung adenocarcinoma cells. Compared with PC14PE6/AS2 (AS2) and CL1-0 cells, apoptotic analysis showed that both A549 and CL1-5 cells were VNR-resistant, while these cells highly expressed GCS at the protein level. VNR treatment significantly converts ceramide to glucosylceramide in VNR-resistant cells; however, pharmacologically inhibiting GCS with (±)-threo-1-Phenyl-2-decanoylamino-3-morpholino-1-propanol hydrochloride (PDMP) induced ceramide accumulation, accompanied by a decrease in glucosylceramide. Under concurrent treatment with VNR and PDMP, an increase in cell apoptosis could be identified; furthermore, genetically silencing GCS confirmed these effects. In VNR-resistant cells, Bcl-xL expression was aberrantly increased, while pharmacologically inhibiting Bcl-xL with ABT-737 sensitized cells to VNRinduced apoptosis. Conversely, enforced expression of Bcl-xL strengthened the survival response of the VNR-susceptible cells AS2 and CL1-0. Without changes in mRNA expression, Bcl-xL was overexpressed independent of β-catenin-mediated transcriptional regulation in VNR-resistant cells. Simultaneous GCS inhibition and VNR treatment caused a decrease in Bcl-xL expression. According to these findings, an increase in GCS caused Bcl-xL augmentation, facilitating VNR resistance in lung adenocarcinoma cells.",
keywords = "Bcl-xL, Glucosylceramide synthase, Lung cancer, Multiple drug-resistances, Vinorelbine",
author = "Chiu, {Wei Hsin} and Su, {Wu Chou} and Li, {Chia Ling} and Chen, {Chia Ling} and Lin, {Chiou Feng}",
year = "2015",
language = "English",
volume = "6",
pages = "20513--20524",
journal = "Oncotarget",
issn = "1949-2553",
publisher = "Impact Journals LLC",
number = "24",

}

TY - JOUR

T1 - An increase in glucosylceramide synthase induces BclxL-mediated cell survival in vinorelbine-resistant lung adenocarcinoma cells

AU - Chiu, Wei Hsin

AU - Su, Wu Chou

AU - Li, Chia Ling

AU - Chen, Chia Ling

AU - Lin, Chiou Feng

PY - 2015

Y1 - 2015

N2 - Reversing drug resistance with concurrent treatment confers anticancer benefits. In this study, we investigated the potential mechanism of glucosylceramide synthase (GCS)-mediated vinca alkaloid vinorelbine (VNR) resistance in human lung adenocarcinoma cells. Compared with PC14PE6/AS2 (AS2) and CL1-0 cells, apoptotic analysis showed that both A549 and CL1-5 cells were VNR-resistant, while these cells highly expressed GCS at the protein level. VNR treatment significantly converts ceramide to glucosylceramide in VNR-resistant cells; however, pharmacologically inhibiting GCS with (±)-threo-1-Phenyl-2-decanoylamino-3-morpholino-1-propanol hydrochloride (PDMP) induced ceramide accumulation, accompanied by a decrease in glucosylceramide. Under concurrent treatment with VNR and PDMP, an increase in cell apoptosis could be identified; furthermore, genetically silencing GCS confirmed these effects. In VNR-resistant cells, Bcl-xL expression was aberrantly increased, while pharmacologically inhibiting Bcl-xL with ABT-737 sensitized cells to VNRinduced apoptosis. Conversely, enforced expression of Bcl-xL strengthened the survival response of the VNR-susceptible cells AS2 and CL1-0. Without changes in mRNA expression, Bcl-xL was overexpressed independent of β-catenin-mediated transcriptional regulation in VNR-resistant cells. Simultaneous GCS inhibition and VNR treatment caused a decrease in Bcl-xL expression. According to these findings, an increase in GCS caused Bcl-xL augmentation, facilitating VNR resistance in lung adenocarcinoma cells.

AB - Reversing drug resistance with concurrent treatment confers anticancer benefits. In this study, we investigated the potential mechanism of glucosylceramide synthase (GCS)-mediated vinca alkaloid vinorelbine (VNR) resistance in human lung adenocarcinoma cells. Compared with PC14PE6/AS2 (AS2) and CL1-0 cells, apoptotic analysis showed that both A549 and CL1-5 cells were VNR-resistant, while these cells highly expressed GCS at the protein level. VNR treatment significantly converts ceramide to glucosylceramide in VNR-resistant cells; however, pharmacologically inhibiting GCS with (±)-threo-1-Phenyl-2-decanoylamino-3-morpholino-1-propanol hydrochloride (PDMP) induced ceramide accumulation, accompanied by a decrease in glucosylceramide. Under concurrent treatment with VNR and PDMP, an increase in cell apoptosis could be identified; furthermore, genetically silencing GCS confirmed these effects. In VNR-resistant cells, Bcl-xL expression was aberrantly increased, while pharmacologically inhibiting Bcl-xL with ABT-737 sensitized cells to VNRinduced apoptosis. Conversely, enforced expression of Bcl-xL strengthened the survival response of the VNR-susceptible cells AS2 and CL1-0. Without changes in mRNA expression, Bcl-xL was overexpressed independent of β-catenin-mediated transcriptional regulation in VNR-resistant cells. Simultaneous GCS inhibition and VNR treatment caused a decrease in Bcl-xL expression. According to these findings, an increase in GCS caused Bcl-xL augmentation, facilitating VNR resistance in lung adenocarcinoma cells.

KW - Bcl-xL

KW - Glucosylceramide synthase

KW - Lung cancer

KW - Multiple drug-resistances

KW - Vinorelbine

UR - http://www.scopus.com/inward/record.url?scp=84940199413&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84940199413&partnerID=8YFLogxK

M3 - Article

VL - 6

SP - 20513

EP - 20524

JO - Oncotarget

JF - Oncotarget

SN - 1949-2553

IS - 24

ER -